- Home
- AGIO vs DBRG Comparison
AGIO vs DBRG Comparison
Compare AGIO & DBRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | DBRG |
|---|---|---|
| Founded | 2007 | 1991 |
| Country | United States | United States |
| Employees | 488 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.1B |
| IPO Year | 2013 | 2009 |
Fundamental Metrics
Financial Performance| Metric | AGIO | DBRG |
|---|---|---|
| Price | $27.39 | $14.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $32.13 | $17.56 |
| AVG Volume (30 Days) | 2.6M | ★ 6.8M |
| Earning Date | 10-30-2025 | 10-30-2025 |
| Dividend Yield | N/A | ★ 0.28% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | $44,791,000.00 | ★ $100,346,000.00 |
| Revenue This Year | $28.75 | N/A |
| Revenue Next Year | $139.45 | $191.07 |
| P/E Ratio | ★ N/A | $235.07 |
| Revenue Growth | ★ 36.26 | N/A |
| 52 Week Low | $22.24 | $6.41 |
| 52 Week High | $46.00 | $15.55 |
Technical Indicators
Market Signals| Indicator | AGIO | DBRG |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 68.28 |
| Support Level | $26.80 | $9.44 |
| Resistance Level | $28.61 | $15.55 |
| Average True Range (ATR) | 1.19 | 0.96 |
| MACD | 0.25 | 0.65 |
| Stochastic Oscillator | 56.00 | 81.88 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centres, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.